Abbott Diabetes Care ART06986 manual References

Models: ART06986

1 93
Download 93 pages 59.3 Kb
Page 92
Image 92

References

References

1.Directive 1999/45/EC of the European Parliament and of the Council of 31 May 1999 concerning the approximation of the laws, regulations and administrative provisions of the Member States relating to the classification, packaging and labelling of dangerous preparations.

2.Schade DS, Eaton RP. Metabolic and clinical significance of ketosis. Special Topics in Endocrinology and Metabolism 1982; 4:1–27.

3.Wiggam MI, O’Kane MJ, Harper R, Atkinson AB, Hadden DR, Trimble ER, Bell PM. Treatment of diabetic ketoacidosis using normalization of blood

3-hydroxybutyrate concentration as the endpoint of emergency management. Diabetes Care 1997; 20:1347–52.

4.Harano Y, Kosugi K, Hyosu T, Suzuki M, Hidaka H, Kashiwagi A, Uno S, Shigeta Y. Ketone bodies as markers for Type 1 (insulin-dependent) diabetes and their value in the monitoring of diabetes control. Diabetologia 1984; 26:343–8.

5.Ubukata E. Diurnal variation of blood ketone bodies in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus patients: The relationship to serum C-peptide immunoreactivity and free insulin. Ann Nutr Metab 1990; 34:333–42.

6.Luzi L, Barrett EJ, Groop LC, Ferrannini E, DeFronzo RA. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. Diabetes 1988; 37:1470–77.

7.Hale PJ, Crase J, Nattrass M. Metabolic effects of bicarbonate in the treatment of diabetic ketoacidosis. Br Med J 1984; 289; 1035–8.

89

Page 92
Image 92
Abbott Diabetes Care ART06986 manual References